Clinical Trial Update: Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update describes evaluating Iparomlimab and Tuvonralimab together with hypofractionated radiotherapy and chemotherapy for head and n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Head and Neck Cancer, Radiotherapy | Phase 2 | Status: RECRUITING